Chemours Co
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CC in the last 30 days.
See all $CC insider activity →Chemours (NYSE: CC) will release Q3 2026 earnings after market close on Nov. 2, 2026, followed by a conference call on Nov. 3, 2026. The webcast and materials will be available on the company's investor relations website. Chemours is a global chemical company with products in various industries, headquartered in Wilmington, Delaware.
Chemours (CC) stock fell 2.3% in pre-market trading after Mizuho downgraded it to Neutral and cut its price target to $15. RBC also downgraded it to Sector Perform, reducing its target to $14. Both analysts cited concerns over slower earnings growth and weak demand in key markets. The stock has lost over 40% in six months, trading near its 52-week low.
Mizuho downgraded Chemours (NYSE:CC) to Neutral from Outperform, lowering its price target to $15 from $18. The downgrade reflects slower-than-expected earnings growth from new refrigerants and concerns about titanium dioxide pigment market stability. Chemours' stock is down over 41% in the past six months, trading at $13.20. The company reported mixed Q2 2026 results, missing earnings and revenue estimates, and settled PFAS-related claims with North Carolina.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CC (Chemours Co). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CC coverage spans financial news, market movers and regulation.
The announcement sets the timing for the upcoming earnings release, but provides no financial details.
Analyst downgrades and lower price targets increase selling pressure on Chemours.
The downgrade and lower target suggest weaker earnings outlook, likely pressuring the stock.
Analyst downgrade with lower price target suggests near-term downside pressure.
Near-term negative sentiment from the downgrade, though it is sell-side framing rather than a new fundamental print.
AlphAI scores every news story that mentions CC with an AI model for sentiment and relevance, and aggregates insider trades from Chemours Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
Chemours (NYSE: CC) will release Q3 2026 earnings after market close on Nov. 2, 2026, followed by a conference call on Nov. 3, 2026. The webcast and materials will be available on the company's investor relations website. Chemours is a global chemical company with products in various industries, headquartered in Wilmington, Delaware.
1 min readChemours (CC) stock fell 2.3% in pre-market trading after Mizuho downgraded it to Neutral and cut its price target to $15. RBC also downgraded it to Sector Perform, reducing its target to $14. Both analysts cited concerns over slower earnings growth and weak demand in key markets. The stock has lost over 40% in six months, trading near its 52-week low.
2 min readMizuho downgraded Chemours (NYSE:CC) to Neutral from Outperform, lowering its price target to $15 from $18. The downgrade reflects slower-than-expected earnings growth from new refrigerants and concerns about titanium dioxide pigment market stability. Chemours' stock is down over 41% in the past six months, trading at $13.20. The company reported mixed Q2 2026 results, missing earnings and revenue estimates, and settled PFAS-related claims with North Carolina.
2 min readRBC downgraded Chemours to Sector Perform from Outperform, lowering its price target to $14 from $22. The firm cited weak titanium dioxide demand and challenges in the refrigerants business. Chemours is a chemical manufacturer.
1 min readUS futures mixed; Nasdaq lags as AI sector rout spreads from Wall Street to Asia, with Kospi down 7%. JPMorgan's FICC revenue misses estimates but raises NII forecast. Premarket: AAPL +0.7%, MSFT +0.4%, NVDA -0.7%. UNH rises 2% on raised guidance; SNDX plunges 10% on trial failure. 10Y yields down 5bps to 5.19%.
7 min readGoldman Sachs reduced its price target for Chemours (NYSE:CC) to $16 from $17, maintaining a Neutral rating. The firm cited a 12-month outlook and potential risks, including pricing volatility and regulatory costs. Chemours shares are down 36% over six months but up 19% year-to-date. The company reported mixed Q2 2026 results, missing earnings and revenue estimates. UBS also downgraded Chemours to Neutral, citing concerns over its refrigerant business.
2 min readGoldman Sachs cut Sherwin-Williams' (SHW) price target to $410 from $420, citing lower peer multiples. It also adjusted targets for Axta (AXTA), PPG (PPG), Tronox (TROX), Kronos (KRO), and Chemours (CC). Goldman noted mixed industry trends, including stable architectural coatings demand and raw material headwinds. Price targets were lowered for SHW, PPG, TROX, KRO, and CC, while AXTA's target was raised.
2 min readChemours, along with other industry groups, has submitted a request to the European Chemicals Agency for a 13-20 year transition period for non-PFAS refrigerants in vehicles. The company argues that developing and deploying alternative refrigerants will take significant time due to technical, safety, and regulatory challenges. The European Union is expected to deliver a final opinion on the PFAS restriction proposal by the end of this year.
2 min readUBS reduced its price target for Chemours from $18 to $16 while maintaining a neutral rating. The stock is currently trading at $13.49, down 1.60% on the day and 4.32% over the past year, but up 14.67% over 5 days. The adjustment reflects changes in valuation and earnings revisions.
1 min readEnvironmental groups allege Chemours is violating agreed-upon discharge limits for PFAS pollution at its Fayetteville Works plant in North Carolina, located upstream of Wilmington. The claims suggest ongoing environmental concerns for the company.
1 min read
